Linked Life Data

20110057

Source:http://linkedlifedata.com/resource/pubmed/id/20110057

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-1-29
pubmed:abstractText
Among diagnostic progress over the last three years in internal medicine, Antisynthetase Syndrome is now more easily recognised with the diffusion of laboratory tests for research of antibodies against tRNA synthetases (Anti JO1, anti PL7, Anti PL12). In two third of cases, these antibodies are found despite absence of antinuclear antibodies. Hence, we have to search them specifically in patients with polyarthritis associated with myositis, cutaneous manifestations (Raynaud phenomenom and "mechanic'hands") and interstitial lung disease. Discovery of asymptomatic mutation in the L ferritin coding sequence help us to better understand the "unexplained" hyperferritinemia. Initially described by japonese gastroenterologists, auto immune pancreatitis in fact a part of a systemic sclerosing disease with a biochemical hallmark: in crease of a subclass of immunoglobulins G (IgG4). A new pediatric disease due to a deficiency of the interleukin1 receptor antagonist (multifocal aseptic osteitis, periostitis, stomatitis, disseminated pustulosis) help us to better understand unexplained auto inflammatory diseases. The therapeutic progress is primarily due to an explosion of biological therapies, particularly four of them very useful for internists (in an off label use) : Interleukin 1 inhibitors (anakinra, Canakinumab) to treat some auto inflammatory diseases (cryopirin associated periodic syndromes and deficency of interleukin 1 receptor antagonist), monoclonal antibody against interleukin 5 (mepolizumab) to treat some hypereosinophilic syndromes and Churg and Strauss angiitis, interleukin 6 inhibitiors to treat multifocal Castleman's disease and adult Still disease, a monoclonal antibody against vascular endothelial growth factor (Bevacizumab) to treat hereditary hemorrhagic telangiectasia.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0151-9638
pubmed:author
pubmed:copyrightInfo
Copyright 2009 Elsevier Masson SAS. All rights reserved.
pubmed:issnType
Print
pubmed:volume
136 Suppl 7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S417-25
pubmed:meshHeading
pubmed-meshheading:20110057-Acute Generalized Exanthematous Pustulosis, pubmed-meshheading:20110057-Amino Acyl-tRNA Synthetases, pubmed-meshheading:20110057-Antibodies, Monoclonal, pubmed-meshheading:20110057-Arthritis, pubmed-meshheading:20110057-Autoantibodies, pubmed-meshheading:20110057-Autoimmune Diseases, pubmed-meshheading:20110057-Biological Markers, pubmed-meshheading:20110057-Drug Therapy, Combination, pubmed-meshheading:20110057-Ferritins, pubmed-meshheading:20110057-Humans, pubmed-meshheading:20110057-Interleukin 1 Receptor Antagonist Protein, pubmed-meshheading:20110057-Interleukin-6, pubmed-meshheading:20110057-Internal Medicine, pubmed-meshheading:20110057-Iron Overload, pubmed-meshheading:20110057-Lung Diseases, Interstitial, pubmed-meshheading:20110057-Mutation, pubmed-meshheading:20110057-Myositis, pubmed-meshheading:20110057-Osteitis, pubmed-meshheading:20110057-Pancreatitis, pubmed-meshheading:20110057-Periostitis, pubmed-meshheading:20110057-Raynaud Disease, pubmed-meshheading:20110057-Stomatitis, pubmed-meshheading:20110057-Syndrome, pubmed-meshheading:20110057-Treatment Outcome
pubmed:year
2009
pubmed:articleTitle
[What's new in internal medicine?].
pubmed:affiliation
Service de Médecine Interne, Hôpital Foch, Suresnes, France. o.bletry@hopital-foch.org
pubmed:publicationType
Journal Article, English Abstract, Review